Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01733147 · ClinicalTrials.gov registry record · Phase 4
Modulation of Esophageal Inflammation in Barrett's Esophagus by Omega-3 Fatty Acids
A Phase 4 study of Obesity and Barrett's Esophagus, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT01733147 is a Phase 4 study of Obesity and Barrett's Esophagus that has completed, run by Mayo Clinic. The registered enrollment target is 60 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01733147, a Phase 4 study of Obesity and Barrett's Esophagus, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done to understand the effect of dietary omega-3 fats in decreasing tissue inflammation in Barrett's esophagus.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Omega-3 polyunsaturated fatty acids
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2012-11 |
| Est. Completion | 2018-09-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01733147
The ClinicalTrials.gov registry entry for NCT01733147 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (93% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01733147 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT01733147 about?
NCT01733147 is a clinical study titled "Modulation of Esophageal Inflammation in Barrett's Esophagus by Omega-3 Fatty Acids". This study is being done to understand the effect of dietary omega-3 fats in decreasing tissue inflammation in Barrett's esophagus.
What is the current status of trial NCT01733147?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2012-11. Estimated completion is 2018-09-12.
What conditions does trial NCT01733147 study?
This clinical trial studies the following conditions: Obesity, Barrett's Esophagus.
What interventions are being tested in trial NCT01733147?
The interventions under investigation include: Placebo (DRUG), Omega-3 polyunsaturated fatty acids (DRUG).
Who is sponsoring clinical trial NCT01733147?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01733147 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
RECRUITING · Phase 4
-
Phenotype-Tailored Lifestyle Intervention for Obesity: A Randomized Trial
RECRUITING · Phase 4
-
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
RECRUITING · Phase 4
-
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion
RECRUITING · Phase 4
-
Fibrosis Lessens After Metabolic Surgery
RECRUITING · Phase 4
-
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.